On 12 November 2026, Sandoz launched Ranluspec, Lupin's biosimilar of ranibizumab, across European markets except Germany.
Ranluspec is a biosimilar of the reference medicine Lucentis. It holds an EU-wide marketing authorisation dated 10 February 2026 and comes in vial and pre-filled syringe forms.
Lupin developed, manufactures and registered the product. Sandoz sells it under a partnership signed in August 2025. In Germany, Sandoz sells a different ranibizumab, Epruvy, under a separate agreement.
Ranibizumab is an antibody fragment that blocks VEGF-A and is injected into the eye. It treats wet age-related macular degeneration, diabetic macular oedema and related retinal diseases.
A biosimilar is a biological medicine highly similar to an approved reference biologic, with no clinically meaningful difference in safety or efficacy. Ranibizumab is a humanised IgG1 Fab fragment. It blocks VEGF-A, which halts abnormal blood-vessel growth (angiogenesis) in the retina. It is injected into the vitreous humour of the eye.
Simple Analogy: A generic copies a simple pill; a biosimilar closely matches a living-cell-made medicine.
Developed, manufactures and registered Ranluspec
Generics and biosimilars company that sells Ranluspec in Europe. Novartis spun it off on 4 October 2023, and it is listed on the SIX Swiss Exchange
Evaluates medicines for the EU. Its EPAR (public assessment report) records the Ranluspec authorisation as 10 February 2026
India's drug regulator. It issues the Guidelines on Similar Biologics together with the Department of Biotechnology
A single authorisation, valid in every EU member state, lets one product be launched across Europe
India's pathway for approving biosimilars. CDSCO published a draft revision on 6 May 2025 to replace the 2016 version and to rely more on advanced analytical comparison
Lupin and Sandoz sign a commercial partnership for the ranibizumab biosimilar
EU-wide marketing authorisation for Ranluspec (EMA record)
Sandoz launches Ranluspec across Europe, excluding Germany
GS Paper 3 > Science and Technology > Biotechnology (biosimilars, monoclonal antibodies)
General Awareness > Business and Science current affairs
A biologic highly similar to an approved reference biologic, with no clinically meaningful difference in safety or efficacy
Vascular endothelial growth factor A, the signal protein that drives new blood-vessel growth. Ranibizumab and bevacizumab both block it
An injection into the vitreous humour of the eye, which is how ranibizumab is given